These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28617331)

  • 1. Hormesis and Defense of Infectious Disease.
    Weis S; Rubio I; Ludwig K; Weigel C; Jentho E
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunodeficiency development in non-specific infectious inflammation].
    Kazimirskiĭ AN; Poriadin GV; Salmasi ZhM
    Patol Fiziol Eksp Ter; 2003; (3):23-6. PubMed ID: 14518105
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage.
    Pirofski LA; Casadevall A
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sepsis: the need for tolerance not complacency.
    Velho TR; Santos I; Póvoa P; Moita LF
    Swiss Med Wkly; 2016; 146():w14276. PubMed ID: 26900874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of immunomodulatory host defense peptides as novel anti-infectives.
    Easton DM; Nijnik A; Mayer ML; Hancock RE
    Trends Biotechnol; 2009 Oct; 27(10):582-90. PubMed ID: 19683819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Countering drug resistance, infectious diseases, and sepsis using metal and metal oxides nanoparticles: Current status.
    Khan ST; Musarrat J; Al-Khedhairy AA
    Colloids Surf B Biointerfaces; 2016 Oct; 146():70-83. PubMed ID: 27259161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human defensins: turning defense into offense?
    de Leeuw E; Lu W
    Infect Disord Drug Targets; 2007 Mar; 7(1):67-70. PubMed ID: 17346213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunomodulatory and anti-inflammatory properties of different antimicrobial agents].
    Guz K; Bugla-Płoskońska G
    Postepy Hig Med Dosw (Online); 2007 Dec; 61():828-37. PubMed ID: 18097341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormesis of drugs for infectious diseases].
    Yu M; Ying G
    Yao Xue Xue Bao; 2016 Mar; 51(3):332-7. PubMed ID: 29858889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crisis in Infectious Diseases: 2 Decades Later.
    Casadevall A
    Clin Infect Dis; 2017 Apr; 64(7):823-828. PubMed ID: 28362950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
    Nicholls EF; Madera L; Hancock RE
    Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in Diagnostic Technology and Management of Infectious Diseases. Topics: III. Progress in Treatment of Infectious Diseases; 1. Antimicrobial use--up to date].
    Aoki Y
    Nihon Naika Gakkai Zasshi; 2014 Nov; 103(11):2714-20. PubMed ID: 27522811
    [No Abstract]   [Full Text] [Related]  

  • 13. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial agents: the new theriac?
    Labro MT
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1363-5. PubMed ID: 23253312
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA Damage Response as a Pharmacological Target for Cancer and Infectious Diseases.
    Poplawski T
    Curr Med Chem; 2019; 26(8):1423-1424. PubMed ID: 31189460
    [No Abstract]   [Full Text] [Related]  

  • 16. Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.
    Lyle NH; Pena OM; Boyd JH; Hancock RE
    Ann N Y Acad Sci; 2014 Sep; 1323():101-14. PubMed ID: 24797961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of anti-inflammatory drugs for infectious diseases.
    Garcia CC; Guabiraba R; Soriani FM; Teixeira MM
    Discov Med; 2010 Dec; 10(55):479-88. PubMed ID: 21189219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular approach for development of new medicaments for chronic infections treatment].
    Zigangirova NA; Gintsburg AL
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):103-9. PubMed ID: 17882840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities for the development of novel therapies based on host-microbial interactions.
    Santos PC; Teixeira MM; Souza DG
    Pharmacol Res; 2016 Oct; 112():68-83. PubMed ID: 27107789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance: A multifaceted problem with multipronged solutions.
    Gil-Gil T; Laborda P; Sanz-García F; Hernando-Amado S; Blanco P; Martínez JL
    Microbiologyopen; 2019 Nov; 8(11):e945. PubMed ID: 31724836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.